The CXCL12 signal pathway is further support for the utility of BTK inhibitors in treating autoimmune diseases listed in Table 1 since CXCL12 is associated with SLE, SJ (102–104), RA (105–108) and MS (109, 110). Here, BTK is linked to myeloid sarcoma.